PPARγ agonists-Antidiabetic drugs with a potential role in the treatment of diseases other than diabetes

Diabetes Research and Clinical Practice

Volumn 78, Issue 3 SUPPL., 2007, Pages

  Jermendy, György ^a  

^a BAJCSY ZSILINSZKY HOSPITAL   (Hungary)

Author keywords

Cardiovascular complications; Diabetes prevention; Insulin resistance; Pioglitazone; Rosiglitazone; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ALZHEIMER DISEASE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG EFFECT; DRUG POTENTIATION; DRUG USE; DRUG WITHDRAWAL; EDEMA; FLUID RETENTION; FRACTURE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIVER TOXICITY; LUNG EDEMA; MARKET; MONOTHERAPY; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PSORIASIS VULGARIS; RISK REDUCTION; SIDE EFFECT; ULCERATIVE COLITIS; WEIGHT GAIN;

EID: 36549070563     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.09.017     Document Type: Article

References (73)

1. Bailey C.J. The rise and fall of troglitazone. Diab. Med. 17 (2000) 414-415
2. Lebovitz H.E., Kreider M., and Freed M.I. Evaluation of liver function in type 2 diabetic patients during clinical trials. Evidence that rosiglitazone does not cause hepatic dysfunction. Diab. Care 25 (2002) 815-821
3. Wagstaff A.J., and Goa K.L. Rosiglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 62 (2002) 1805-1837
4. Waugh J., Keating G.M., Plosker G.L., Easthope S., and Robinson D.M. Pioglitazone: a review of its use in type 2 diabetes. Drugs 66 (2006) 85-109 (Erratum: Drugs 66 (2006) 340-341)
5. Diamant M., and Heine R.J. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 63 (2003) 1373-1405
6. Elte J.W., and Blickle J.F. Thiazolidinediones for the treatment of type 2 diabetes. Eur. J. Intern. Med. 18 (2007) 18-25
7. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43 (2000) 527-550
8. Jermendy G., and Csermely P. Thiazolidinediones-a new class of oral antidiabetic drugs. Orv. Hetil. 142 (2001) 1547-1554
9. Stumvoll M., and Haring H.U. Glitazones: clinical effects and molecular mechanisms. Ann. Med. 34 (2002) 217-224
10. Lowell B.B. PPARγ: an essential regulator of adipogenesis and modulator of fat cell function. Cell 99 (1999) 239-242
11. Hauner H. The mode of action of thiazolidinediones. Diab. Metab. Res. Rev. 18 Suppl. 2 (2002) S10-S15
12. Goldberg R.B. Impact of thiazolidenediones on serum lipoprotein levels. Curr. Atheroscler. Rep. 8 (2006) 397-404
13. Mori Y., Murakawa Y., Okada K., Horikoshi H., Yokoyama J., Tajima N., et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diab. Care 22 (1999) 908-912
14. Akazawa S., Sun F., Ito M., Kawasaki E., and Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diab. Care 23 (2000) 1067-1071
15. Nakamura T., Funahashi T., Yamashita S., Nishida M., Nishida Y., Takahashi M., et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation-double-blind placebo-controlled trial. Diab. Res. Clin. Pract. 54 (2001) 181-190
16. Ghanim H., Dhindsa S., Aljada A., Chaudhuri A., Viswanathan P., and Dandona P. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J. Clin. Endocrinol. Metab. 91 (2006) 3553-3558
17. Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
18. Bakris G.L., Ruilope L.M., McMorn S.O., Weston W.M., Heise M.A., Freed M.I., et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J. Hypertens. 24 (2006) 2047-2055
19. St John Sutton M., Rendell M., Dandona P., Dole J.F., Murphy K., Patwardhan R., et al. A comparison of the effect of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diab. Care 25 (2002) 2058-2064
20. Sarafidis P.A., and Nilsson P.M. The effects of thiazolidinediones on blood pressure levels-a systematic review. Blood Press 15 (2006) 135-150
21. Martens F.M.A.C., Visseren F.L.J., Lemay J., Koning de E.J.P., and Rabelink T.J. Metabolic and additional vascular effects of thiazolodinediones. Drugs 62 (2002) 1463-1480
22. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
23. Ishibashi M., Egashira K., Hiasa K., Onoue S., Ni W., and Zhao Q. Antiinflammatory and antiatherosclerotic effects of pioglitazone. Hypertension 40 (2002) 687-693
24. Derosa G., Dangelo A., Ragonesi P.D., Ciccarelli L., Piccinni M.N., and Pricolo F. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J. Int. Med. Res. 34 (2006) 545-555
25. Marx N., Froehlich J., Siam L., Ittner J., Wierse G., Schmidt A., et al. Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 283-288
26. Natali A., Baldeweg S., Toschi E., Capaldo B., Barbaro D., and Gastaldelli A. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diab. Care 27 (2004) 1349-1357
27. Hetzel J., Balletshofer B., Rittig K., Walcher D., Kratzer W., Hombach V., et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1804-1809
28. Pfutzner A., Hohberg C., Lubben G., Pahler S., Pfutzner A.H., Kann P., et al. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm. Metab. Res. 37 (2005) 510-515
29. Finegood D.T., McArthur M.D., Kojwang D., Thomas M.J., Topp B.G., Leonard T., et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50 (2001) 1021-1029
30. Walter H., and Lubben G. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. Drugs 65 (2005) 1-13
31. Pershadsingh H.A. Peroxisome proliferator-activated receptor-γ: therapeutic target for diseases beyond diabetes: quo vadis?. Exp. Opin. Invest. Drugs 13 (2004) 215-228
32. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., and Freed M.I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 86 (2001) 280-288
33. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diab. Care 28 (2005) 1547-1554
34. Kendall D.M. Thiazolidinediones. The case for early use. Diab. Care 29 (2006) 154-157
35. Tang W.H., Fracis G.S., Hoogwerf B.J., and Young J.B. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. JACC 41 (2003) 1394-1398
36. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation 108 (2003) 2941-2948
37. Pavo I., Jermendy G., Varkonyi T., Kerenyi Z., Gyimesi A., Shoustov S., et al. Effect of pioglitazone compared with metformin on glycemic control and indications of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 88 (2003) 1637-1645
38. The ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355 (2006) 2427-2443
39. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49 (2006) 1711-1721 (Erratum: Diabetologia 49 (2006) 2816-2818)
40. Fonseca V., Rosenstock J., Patwardhan R., and Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial. JAMA 283 (2000) 1695-1702
41. Jones T.A., Sautter M., Van Gaal L.F., and Jones N.P. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diab. Obes. Metab. 5 (2003) 163-170
42. Wolffenbuttel B.H.R., Gomis R., Squatrito S., Jones N.P., and Patwardhan R.N. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diab. Med. 17 (2000) 40-47
43. Bell D.S.H., and Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr. Pract. 8 (2002) 271-275
44. Rosenstock J., Sugimoto D., Strange P., Stewart J.A., Soltes-Rak E., and Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diab. Care 29 (2006) 554-559
45. Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 (2002) 2796-2803
46. Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., Ochoa C., et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55 (2006) 517-522
47. Knowler W.C., Hamman R.F., Edelstein S.L., Barrett-Connor E., Ehrmann D.A., Walker E.A., et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54 (2005) 1150-1156
48. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
49. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., and Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 86 (2001) 3452-3456
50. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino Sr. R.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
51. Sidhu J.S., Kaposzta Z., Markus H.S., and Kaski J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 930-934
52. Choi D., Kim S.K., Choi S.H., Ko Y.G., Ahn C.W., Jang Y., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diab. Care 27 (2004) 2654-2660
53. Nishio K., Sakurai M., Kusuyama T., Shigemitsu M., Fukui T., Kawamura K., et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diab. Care 29 (2006) 101-106
54. The PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
55. Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet 366 (2005) 1241-1242
56. Richter B., Bandeira-Echtler E., Bergerhoff K., Clar C., and Ebrahim S.H. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 4 (2006) CD006060
57. Erdmann E., Charbonnel B., Dormandy J., Massi-Benedetti M., Skene A., Wilcox R., et al. Pioglitazone treatment in patients with type 2 diabetes and a history of myocardial infarction: subgroup analyses from PROactive stratified by gender, age, and duration of diabetes. Diabetologia 49 Suppl. 1 (2006) 755 (abstract)
58. Wilcox R., Bousser M.G., Dormandy J., and Perez A. Effect of pioglitazone in stroke prevention in type 2 diabetes: a prespecified subgroup analysis of PROactive. Diabetes 55 Suppl. 1 (2006) A138 (abstract)
59. Home P.D., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., Dargie H., et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 48 (2005) 1726-1735
60. Macfarlane D.P., and Fisher M. Thiazolidinediones in patients with diabetes mellitus and heart failure. Am. J. Cardiovasc. Drugs 6 (2006) 297-304
61. Ratziu V., Jacqueminer S., Giral P., Podevin P., Serfaty L., Charlotte F., et al. A one-year, randomized, placebo-controlled, double-blind trial of rosiglitazone in non alcoholic steatohepatitis: results of the FLIRT pilot trial. Diabetologia 49 Suppl. 1 (2006) 755 (abstract)
62. Lord J.M., Flight I.H., and Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327 (2003) 951-953
63. Stout D.L., and Fugate S.E. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy 25 (2005) 244-252
64. Pershadsingh H.A., Sproul J.A., Benjamin E., Finnegan J., and Amin N.M. Treatment of psoriasis with troglitazone therapy. Arch. Dermatol. 134 (1998) 1304-1305
65. Robertshaw H., and Friedmann P.S. Pioglitazone: a promising new therapy for psoriasis. Br. J. Dermatol. 152 (2005) 189-191
66. Shafig N., Malhotra S., Pandhi P., Gupta M., Kumar B., and Sandhu K. Pioglitazone versus placebo in patients with plaque psoriasis. Int. J. Dermatol. 44 (2005) 328-333
67. Friedmann P.S., Cooper H.L., and Healy E. Peroxisome proliferator-activated receptors and their relevance to dermatology. Acta Derm. Venereol. 85 (2005) 194-202
68. Hashimoto Y., and Nakahara K. Improvement of asthma after administration of pioglitazone. Diab. Care 25 (2002) 401
69. Lewis J.D., Lichtenstein G.R., Stein R.B., Deren J.J., Judge T.A., Fogt F., et al. An open-label trial of the PPARγ-ligand rosiglitazone for active ulcerative colitis. Am. J. Gastroenterol. 96 (2001) 3323-3328
70. Wohl D.A. Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV infection and its therapies. Top. HIV Med. 12 (2004) 89-93
71. Rumi M.A., Ishihara S., Kazumori H., Kadowaki Y., and Kinoshita Y. Can PPAR gamma ligands be used in cancer therapy?. Curr. Med. Chem. Anticancer Agents 4 (2004) 465-477
72. Watson G.S., and Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17 (2003) 27-45
73. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13 (2005) 950-958